Thermo Fisher 18 may 2026 Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden - Business Wire
Revvity 18 may 2026 Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance - simplywall.st
Eli Lilly 18 may 2026 Eli Lilly and Company Enters $2.3 Billion Agreement to Acquire Ajax Therapeutics - The Healthcare Technology Report.
Philips 18 may 2026 Philips introduces SmartIQ to address the trade-off between image quality and radiation dose in coronary procedures - Philips
Boston Scientific 18 may 2026 Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business - Reuters
Eli Lilly 18 may 2026 Vincetage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators - Fierce Biotech
Agilent 18 may 2026 Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading - Yahoo Finance Singapore
Brady Corporation 18 may 2026 Brady Corporation Reports Record Adjusted EPS in its Fiscal 2026 Third Quarter and Raises its Fiscal 2026 Adjusted EPS Guidance - The Manila Times
Brady Corporation 18 may 2026 Sitryx to Participate in Upcoming Investor Conferences - The Manila Times
Lonza News 18 may 2026 Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement - CHEManager
Endpoints News 18 may 2026 FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension
FierceBiotech 18 may 2026 Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3
MACHEREY-NAGEL GmbH & Co. KG 18 may 2026 $1 Billion Human Identification Market Analysis by Product, Technology, Application, End User and Region - Forecast to 2031 - Yahoo Finance
Ningbo HEALTH Gene Technologies Co., Ltd. 18 may 2026 $1 Billion Human Identification Market Analysis by Product, Technology, Application, End User and Region - Forecast to 2031 - Yahoo! Finance Canada
FierceBiotech 18 may 2026 Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial